These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 5484240)

  • 21. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [European competition and financial impact].
    Béchon C
    Transfus Clin Biol; 2008 Nov; 15(5):246. PubMed ID: 18930690
    [No Abstract]   [Full Text] [Related]  

  • 23. Chromatographic removal of viruses from plasma derivatives.
    Burnouf T
    Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Purity of biological products: related and unrelated impurities.
    Herman AC
    Dev Biol Stand; 1998; 96():57-62. PubMed ID: 9890517
    [No Abstract]   [Full Text] [Related]  

  • 25. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes to biological source materials.
    Sewerin K; Shacter E; Robertson J; Wallerius C
    Biologicals; 2006 Mar; 34(1):71-2. PubMed ID: 16480893
    [No Abstract]   [Full Text] [Related]  

  • 27. A safer plasma supply from remunerated donors--"The Immuno/Community Bio-Resources experiment".
    Waytes AT; Igel H; Zerlauth G; Wappler N; Lee M; Schwarz O
    Dev Biol (Basel); 2000; 102():37-51. PubMed ID: 10794089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cellular therapies: the Australian perspective.
    Wall DM; Prince HM
    Cytotherapy; 2003; 5(4):284-8. PubMed ID: 12944233
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Points to consider on virus safe plasma products.
    Biologicals; 1995 Jun; 23(2):193-5. PubMed ID: 7546664
    [No Abstract]   [Full Text] [Related]  

  • 30. The quality control of biotechnology products.
    Federici MM
    Biologicals; 1994 Jun; 22(2):151-9. PubMed ID: 7917231
    [No Abstract]   [Full Text] [Related]  

  • 31. Transmissible spongiform encephalopathies (TSE): minimizing the risk of transmission by biological/biopharmaceutical products: an industry perspective.
    Kozak RW; Golker CF; Stadler P
    Dev Biol Stand; 1996; 88():257-64. PubMed ID: 9119148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Concentrate of coagulation factor IX: viral validation of the thermoinactivation process].
    Zahorska R; Buchowicz I; Ejduk A
    Acta Haematol Pol; 1995; 26(4):421-4. PubMed ID: 8571744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future approaches to ensure the viral safety of biopharmaceuticals.
    Brorson K; Norling L; Hamilton E; Lute S; Lee K; Curtis S; Xu Y
    Dev Biol (Basel); 2004; 118():17-29. PubMed ID: 15645669
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of potency for well characterized biotechnology proteins.
    Finbloom DS
    Dev Biol Stand; 1998; 96():63-4. PubMed ID: 9890518
    [No Abstract]   [Full Text] [Related]  

  • 36. [Organizational problems of the production of biological preparations of blood].
    Barsukov AK; Obukhov VA; Nesterova OIu; Ushnurtseva SA; Lapin KA; Kozhevnikova OV; Kuznetsov AI; Makshakov VA; Ivanov GG; Minaev AG; Minaeva EV; Perevozchikov AG; Shirobokova MS; Susekov VE; Karpov VG; Vozdvizhenskiĭ VV
    Med Tekh; 1996; (2):37-8. PubMed ID: 8754109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
    Hilfenhaus J; Niedrig M; Nowak T
    Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of product comparability.
    Builder SE
    Dev Biol Stand; 1998; 96():83-90. PubMed ID: 9890520
    [No Abstract]   [Full Text] [Related]  

  • 39. [Requirements for microorganism strains for the preparation of biologicals].
    Selivanov AV; Kirillov LV; Borisovich IuF
    Veterinariia; 1980 Apr; (4):33-5. PubMed ID: 7395074
    [No Abstract]   [Full Text] [Related]  

  • 40. [Plasma fractionation. Progress, problems and perspectives].
    Burnouf T
    Ann Pharm Fr; 1994; 52(3):124-36. PubMed ID: 7998759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.